GOOG: $318.39 ▼ -2.23 (-0.70%)MU: $226.65 ▼ -7.51 (-3.21%)AMD: $215.98 ▼ -1.62 (-0.74%)AVGO: $381.03 ▲ 0.42 (0.11%)LLY: $1,014.49 ▼ -19.07 (-1.85%)LRCX: $157.09 ▼ -2.66 (-1.67%)AMAT: $269.44 ▲ 0.81 (0.30%)MRK: $100.89 ▼ -1.38 (-1.35%)CRM: $247.46 ▲ 8.74 (3.66%)LIN: $403.73 ▼ -5.42 (-1.32%)META: $661.53 ▲ 21.93 (3.43%)NFLX: $103.22 ▼ -0.74 (-0.71%)ORCL: $214.33 ▲ 6.60 (3.18%)USDEUR: $0.86 ▲ 0.00 (0.23%)ARGX.BR: $792.20 ▼ -6.80 (-0.85%)ASML.AS: $957.30 ▼ -6.10 (-0.63%)AZN.L: $13,514.00 ▼ -180.00 (-1.31%)BARC.L: $439.20 ▲ 5.85 (1.35%)BBVA.MC: $19.10 ▲ 0.41 (2.19%)ENR.DE: $117.10 ▲ 3.05 (2.67%)MC.PA: $633.10 ▲ 2.80 (0.44%)RWE.DE: $43.59 ▼ -0.18 (-0.41%)STAN.L: $1,662.00 ▲ 1.50 (0.09%)UCB.BR: $239.90 ▲ 0.10 (0.04%)INTC: $40.50 ▼ -3.26 (-7.45%)XAUUSD: $4,209.06 ▲ 5.94 (0.14%)WBD: $24.54 ▼ -0.03 (-0.12%)WDC: $161.00 ▲ 5.41 (3.48%)IEF: $96.67 ▼ -0.30 (-0.31%)TLT: $88.58 ▼ -0.48 (-0.54%)CAT: $599.15 ▲ 7.66 (1.30%)TMO: $575.24 ▼ -5.21 (-0.90%)AIR.PA: $197.02 ▼ -1.10 (-0.56%)BATS.L: $4,342.00 ▲ 0.00 (0.00%)BP.L: $465.00 ▲ 1.00 (0.22%)CFR.SW: $173.10 ▼ -0.45 (-0.26%)EL.PA: $303.20 ▼ -5.60 (-1.81%)GSK.L: $1,826.00 ▼ -7.00 (-0.38%)LLOY.L: $96.96 ▲ 1.00 (1.04%)RIO.L: $5,494.00 ▼ -10.00 (-0.18%)ROG.SW: $310.10 ▼ -3.70 (-1.18%)AAPL: $280.70 ▼ -3.45 (-1.21%)JNJ: $202.48 ▼ -2.85 (-1.39%)BAYN.DE: $33.58 ▼ -0.68 (-1.97%)GLEN.L: $382.90 ▼ -0.20 (-0.05%)SAN.MC: $9.48 ▲ 0.17 (1.78%)ISRG: $568.63 ▼ -1.08 (-0.19%)IBE.MC: $17.93 ▼ -0.09 (-0.47%)TTE.PA: $57.18 ▲ 0.14 (0.25%)STX: $265.63 ▲ 6.96 (2.69%)AMZN: $229.11 ▼ -3.27 (-1.41%)MSFT: $480.84 ▲ 3.11 (0.65%)NVDA: $183.38 ▲ 3.79 (2.11%)IBB: $172.11 ▼ -0.12 (-0.07%)XBI: $123.25 ▲ 1.42 (1.17%)SOXX: $306.28 ▼ -3.08 (-1.00%)

Company Details

ARS Pharmaceuticals, Inc.

SPRY - NASDAQ

Identifiants & Marche

Ticker SPRY
ISIN US82835W1080
CIK 0001671858
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Voir l'evolution du cours Retour